285 related articles for article (PubMed ID: 36232997)
1. New Oxazolo[5,4-
Sochacka-Ćwikła A; Mączyński M; Czyżnikowska Ż; Wiatrak B; Jęśkowiak I; Czerski A; Regiec A
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232997
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
3. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
4. New Schiff bases derived from dimethylpyridine-1,2,4-triazole hybrid as cytotoxic agents targeting gastrointestinal cancers: Design, synthesis, biological evaluation and molecular docking studies.
Strzelecka M; Wiatrak B; Jawień P; Czyżnikowska Ż; Świątek P
Bioorg Chem; 2023 Oct; 139():106758. PubMed ID: 37540951
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2.
Abou-Seri SM; Eissa AAM; Behery MGM; Omar FA
Bioorg Chem; 2021 Nov; 116():105334. PubMed ID: 34534755
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
Hassan A; Badr M; Abdelhamid D; Hassan HA; Abourehab MAS; Abuo-Rahma GEA
Bioorg Chem; 2022 Mar; 120():105631. PubMed ID: 35091289
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
[TBL] [Abstract][Full Text] [Related]
10. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
[TBL] [Abstract][Full Text] [Related]
11. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking.
Hassan RA; Hamed MIA; Abdou AM; El-Dash Y
Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190
[TBL] [Abstract][Full Text] [Related]
12. Novel Pyrimidine Derivatives as Potential Anticancer Agents: Synthesis, Biological Evaluation and Molecular Docking Study.
Tylińska B; Wiatrak B; Czyżnikowska Ż; Cieśla-Niechwiadowicz A; Gębarowska E; Janicka-Kłos A
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917090
[TBL] [Abstract][Full Text] [Related]
13. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 5-(or 6)-benzoxazoles and oxazolo[4,5-b]pyridines as novel candidate antitumor agents targeting hTopo IIα.
Karatas E; Foto E; Ertan-Bolelli T; Yalcin-Ozkat G; Yilmaz S; Ataei S; Zilifdar F; Yildiz I
Bioorg Chem; 2021 Jul; 112():104913. PubMed ID: 33945950
[TBL] [Abstract][Full Text] [Related]
16. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, photophysical properties, anticancer evaluation, and molecular docking studies of new pyrimidine linked 4-arylidene-thiazolidin-4-ones as potent anticancer agents.
Jame R
Luminescence; 2024 Jan; 39(1):e4672. PubMed ID: 38286597
[TBL] [Abstract][Full Text] [Related]
18.
Chowrasia D; Jafri A; Azad I; Rais J; Sharma N; Khan F; Kumar A; Kumar S; Arshad M
J Biomol Struct Dyn; 2022 Nov; 40(18):8569-8586. PubMed ID: 33955334
[TBL] [Abstract][Full Text] [Related]
19. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
